Figure 3

Schematic view of the application sequences of the IMPs. (A) Patients in group 1 of phase I or II will receive the IMPs in the sequence depicted here. (B) Group 2 of phase II, which consists of patient that receive neoadjuvant therapy for resectable tumors will receive the IMPs in the sequence portrayed here.